Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice

European Journal of Pharmacology

Volumn 552, Issue 1-3, 2006, Pages 170-175

  Pan, Si Yuan ^a   Yang, Rong ^a   Dong, Hang ^a   Yu, Zhi ling ^b   Ko, Kam Ming ^c  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^c HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Bifendate; Fatty liver; Fenofibrate; Hypercholesterolemia; Total cholesterol; Triglyceride

Indexed keywords

BILE SALT; BIPHENYLDICARBOXYLATE; CARBOXYLIC ACID DERIVATIVE; CHOLESTEROL; FENOFIBRATE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FATTY LIVER; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; TISSUE LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; BILE ACIDS AND SALTS; BIPHENYL COMPOUNDS; CHOLESTEROL; CHOLESTEROL, DIETARY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY LIVER; HYPERCHOLESTEROLEMIA; MALE; MICE; MICE, INBRED ICR; PROCETOFEN; TIME FACTORS; TRIGLYCERIDES;

EID: 33750471637     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.09.011     Document Type: Article

References (36)

1. Akyol G., Erdem O., and Yilmaz G. Nonalcoholic fatty liver disease. Correlation with histology and viral hepatitis. Saudi Med. J. 26 (2005) 1904-1910
2. Andersson Y., Majd Z., Lefebvre A.M., Martin G., Sechkin A.V., Kosykh V., Fruchart J.C., Najib J., and Staels B. Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 115-121
3. Aronow W.S. Managing hyperlipidaemia in the elderly: special considerations for a population at high risk. Drug Aging 23 (2006) 181-189
4. Benedetti A. Attraction and growing interest for the fatty liver by the scientific associations. Eur. Rev. Med. Pharmacol. Sci. 9 (2005) 251-252
5. Comar K.M., and Sterling R.K. Review article: drug therapy for non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 23 (2006) 207-215
6. Csaszar A. Hypertriglyceridemia, the coronary heart disease risk marker "solved". Acta Physiol. Hung. 92 (2005) 109-120
7. Cui S., Wang M., and Fan G. Anti-HBV efficacy of bifendate in treatment of chronic hepatitis B, a primary study. Zhonghua YiXue ZaZhi 25 (2002) 538-540
8. Fan J.G., Zhu J., Li X.J., Chen L., Lu Y.S., Li L., Dai F., Li F., and Chen S.Y. Fatty liver and the metabolic syndrome among Shanghai adults. J. Gastroenterol. Hepatol. 12 (2005) 1825-1832
9. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 S1 (2006) 99-112
10. Frederiksen K.S., Wulf E.M., Wassermann K., Sauerberg P., and Fleckner J. Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists. J. Mol. Endocrinol. 30 (2003) 317-329
11. Grieco A., Forgione A., Miele L., Vero V., Greco A.V., Gasbarrini A., and Gasbarrini G. Fatty liver and drugs. Eur. Rev. Med. Pharmacol. Sci. 9 (2005) 261-263
12. Guan L.P., Nan J.X., Jin X.J., Jin Q.H., Kwak K.C., Chai K.Y., and Quan Z.S. Protective effects of chalcone derivatives for acute liver injury in mice. Arch. Pharm. Res. 28 (2005) 81-86
13. Gui S.Y., Wei W., Wang H., Wu L., Sun W.Y., and Wu C.Y. Protective effect of fufanghuangqiduogan against acute liver injury in mice. World J. Gastroenterol. 21 (2005) 2984-2989
14. Jeong S., Han M., Lee H., Kim M., Kim J., Nicol C.J., Kim B.H., Choi J.H., Nam K.H., Oh G.T., and Yoon M. Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism 53 (2004) 1284-1289
15. Jian W.Y., Shu C.L., and Gui Q.W. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int. 26 (2006) 166-172
16. Ko R.K.M., and Mak D.H.F. Schisandrin B and other dibenzocyclooctadiene lignans. In: Packer L., Halliwell B., and Ong C.N. (Eds). Modern Herbal Medicine: Molecular Basis in Health and Disease Management (2004), Marcel Dekker, New York 289-314
17. Lamarche B., Rashid S., and Lewis G. HDL metabolism in hypertriglyceridemic states: an overview. Clin. Chim. Acta 286 (1999) 145-161
18. Lin Y.C., Lo H.M., and Chen J.D. Sonographic fatty liver, overweight and ischemic heart disease. World J. Gastroenterol. 11 (2005) 4838-4942
19. Liu G.T. From the study of Fructus Schizandrae to the discovery of biphenyl dimethyl-dicarboxylate. Acta Pharm. Sin. 18 (1983) 714-720
20. Liu K.T., Cresteil T., Columelli S., and Lesca P. Pharmacological properties of dibenzo[a,c]cyclooctene derivatives isolated from Fructus Schizandrae chinensis II. Induction of phenobarbital-like hepatic monooxygenases. Chem. Biol. Interact. 39 (1982) 315-330
21. Liu G.T., Wei H.L., and Song Z.Y. Further studies on the protective action of biphenyl dimethyl-dicarboxylate (BDD) against experimental liver injury in mice. Acta Pharm. Sin. 17 (1982) 101-105
22. Mager D.R., and Roberts E.A. Nonalcoholic fatty liver disease in children. Clin. Liver Dis. 10 (2006) 109-131
23. Mancini F.P., Lanni A., Sabatino L., Moreno M., Giannino A., Contaldo F., Colantuoni V., and Goglia F. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett. 491 (2001) 154-158
24. McKenney J.M., Farnier M., Lo K.W., Bavs H.E., Perevozkava I., Carlson G., Davies M.J., Mitchel Y.B., and Gumbiner B. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J. Am. Coll. Cardiol. 47 (2006) 1584-1587
25. Miura Y., Hosono M., Oyamada C., Odai H., Oikawa S., and Kondo K. Dietary isohumulones, the bitter components of beer, raise plasma HDL-cholesterol levels and reduce liver cholesterol and triacylglycerol contents similar to PPARalpha activations in C57BL/6 mice. Br. J. Nutr. 93 (2005) 559-567
26. Mounie J., Champion L., Goudonnet H., Escousse A., and Trchot R.C. Inductive effects of fenofibrate and metabolism of phenobarbital. Fundam. Clin. Pharmacol. 2 (1988) 259-265
27. Packard C.J. Overview of fenofibrate. Eur. Heart J. 19 Suppl A (1998) 62-65
28. Pan S.Y., Dong H., Han Y.F., Li W.Y., Zhao X.Y., and Ko K.M. A novel experimental model of acute hypertriglyceridemia induced by schisandrin B. Eur. J. Pharmacol. 537 (2006) 200-204
29. Pan S.Y., Yang R., Han Y.Y., Dong H., Feng X.D., Li N., Geng W., and Ko K.M. High doses of bifendate elevate serum and hepatic triglyceride levels in rabbits and mice: animal models of acute hypertriglyceridemia. Acta Pharmacol. Sin. 27 (2006) 673-678
30. Park Y.W., Zhu S., Palaniappan L., Heshka S., Carnethon M.R., and Heymsfield S.B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 163 (2003) 1988-1994
31. Sanval A.I. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2 (2005) 46-53
32. Sasaki J., Yamamoto K., and Ageta M. Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study. Clin. Ther. 24 (2002) 1614-1626
33. Tilg H., and Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2 (2005) 148-155
34. Tsimihodimos V., Miltiadous G., Daskalopoulou S.S., Mikhailidis D.P., and Elisaf M.S. Fenofibrate: metabolic and pleiotropic effects. Curr. Vasc. Pharmacol. 3 (2005) 87-98
35. Tsutsumi And M., and Takase S. Effect of fenofibrate on fatty liver in rats treated with alcohol. Alcohol Clin. Exp. Res. 25 6 Suppl (2001) 75S-79S
36. Zou C.C., Liang L., Hong F., Fu J.F., and Zhao Z.Y. Serum adiponectin, resistin levels and non-alcoholic fatty liver disease in obese children. Endocr. J. 52 (2005) 519-524